SCT promoter methylation is a highly discriminative biomarker for lung and many other cancers
Abstract
Aberrant DNA methylation has long been implicated in cancers. In this work we present a highly discriminative DNA methylation biomarker for non-small cell lung cancers and fourteen other cancers. Based on 69 NSCLC cell lines and 257 cancer-free lung tissues we identified a CpG island in SCT gene promoter which was verified by qMSP experiment in 15 NSCLC cell lines and 3 immortalized human respiratory epithelium cells. In addition, we found that SCT promoter was methylated in 23 cancer cell lines involving >10 cancer types profiled by ENCODE. We found that SCT promoter is hyper-methylated in primary tumors from TCGA lung cancer cohort. Additionally, we found that SCT promoter is methylated at high frequencies in fifteen malignancies and is not methylated in ∼1000 non-cancerous tissues across >30 organ types. Our study indicates that SCT promoter methylation is a highly discriminative biomarker for lung and many other cancers.
Subject Area
- Biochemistry (11736)
- Bioengineering (8749)
- Bioinformatics (29186)
- Biophysics (14964)
- Cancer Biology (12086)
- Cell Biology (17403)
- Clinical Trials (138)
- Developmental Biology (9418)
- Ecology (14176)
- Epidemiology (2067)
- Evolutionary Biology (18299)
- Genetics (12235)
- Genomics (16795)
- Immunology (11863)
- Microbiology (28066)
- Molecular Biology (11582)
- Neuroscience (60936)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4956)
- Plant Biology (10423)
- Synthetic Biology (2883)
- Systems Biology (7338)
- Zoology (1650)